PeptidePlaza
The Free Peptide Reference

Taspoglutide

From PeptidePlaza, the free peptide reference · Entry #1138 · Metabolic · Sources fetched 2026-09-11 · Editorial standards

Taspoglutide (also known as taspoglutida, taspoglutidum, ITM 077, BIM 51077) is a metabolic research peptide. Taspoglutide is a glucagon-like peptide 1 receptor agonist that was investigated for the treatment of Type 2 Diabetes Mellitus.

Taspoglutide, also known as ITM 077, is a glucagon-like peptide 1 receptor agonist. It functions by activating the GLP-1 receptor. The compound has been studied for its potential in treating Type 2 Diabetes Mellitus, reaching Phase 3 clinical trials. Research has explored its structure and dynamics when bound to GLP-1R-Gs complexes, as well as its cardiovascular safety in individuals with type 2 diabetes. Studies also include comparisons of its efficacy and safety among GLP-1 receptor agonists.

1 Mechanism of action

Glucagon-like peptide 1 receptor agonist (agonist)

Primary targets: Glucagon-like peptide 1 receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

  • Diabetes Mellitus, Type 2

3 Chemical and physical properties

CAS number275371-94-3
Molar mass3339.7 g/mol
Purity (typical)Not independently verified
Storage−20 °C, lyophilised powder, desiccated
SolubilitySterile water / bacteriostatic water
Receptors / targetsGlucagon-like peptide 1 receptor

4 Research studies (8)

  1. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
    Cell reports (2021)
  2. Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis
    Diabetes, obesity & metabolism (2025) · Systematic Review
  3. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
    Expert opinion on investigational drugs (2009) · Review
  4. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials
    Diabetes, obesity & metabolism (2015) · Meta-Analysis
  5. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis
    Annals of internal medicine (2016) · Systematic Review
  6. The efficacy of placebo-adjusted taspoglutide on body weight reduction in clinical trials
    Die Pharmazie (2015) · Meta-Analysis
  7. PEGylated prodrugs of antidiabetic peptides amylin and GLP-1
    Journal of controlled release : official journal of the Controlled Release Society (2018)
  8. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial
    The Journal of clinical endocrinology and metabolism (2012) · RCT

5 Safety and risk profile

5.1 Regulatory status

Taspoglutide is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.

Safety data disclaimer. Safety assessments are based on published literature and are for educational reference only. Clinical evidence varies significantly between peptides. Always consult primary research and current regulatory guidance.

6 Frequently asked questions

What is taspoglutide?
Taspoglutide is a glucagon-like peptide 1 receptor agonist. It was developed as a potential treatment for Type 2 Diabetes Mellitus and reached Phase 3 clinical trials.
How does taspoglutide work?
Taspoglutide functions as an agonist of the glucagon-like peptide 1 receptor. By activating this receptor, it aims to exert its therapeutic effects, particularly in the context of Type 2 Diabetes Mellitus.
What is taspoglutide studied for?
Taspoglutide has been studied for its use in Type 2 Diabetes Mellitus. Research has also focused on its cardiovascular safety and its comparison with other GLP-1 receptor agonists regarding efficacy and safety.
What is the regulatory status of taspoglutide?
Taspoglutide reached Phase 3 in its clinical development for Type 2 Diabetes Mellitus, indicating it progressed significantly through the clinical trial process.

7 References

  1. Taspoglutide — compound summary PubChem. View source
  2. Taspoglutide — molecule record ChEMBL. View source
  3. Taspoglutide — published literature (61 records) PubMed. View source

Related compounds

Entries that share a target, a mechanism, or a research area with Taspoglutide.

Dulaglutideapproved

Also targets Glucagon-like peptide 1 receptor

Dulaglutide, marketed as TRULICITY, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control and reduce cardiovascular risk in adults with type 2 diabetes mellitus.

Lixisenatideapproved

Also targets Glucagon-like peptide 1 receptor

Lixisenatide, also known as Adlyxin, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes mellitus.

Albiglutideapproved

Also targets Glucagon-like peptide 1 receptor

Albiglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus.

Elsiglutidemetabolic

Also metabolic

Elsiglutide is a glucagon-like peptide 2 receptor agonist currently in Phase 2 clinical trials for the treatment of diarrhea.

8 See also

For research reference only. Not medical advice. Peptides may be regulated or restricted in your jurisdiction. Entry validated by the PeptidePlaza Biomedical Research Desk; see editorial standards.